THERAPY DOSSIER · th-3190217c2f31

Dioscin

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29091898 ↗2017Reported benefit

Protective effect of dioscin against thioacetamide-induced acute liver injury via FXR/AMPK signaling pathway in vivo.

MixedChemical/toxinSprague-Dawley rats and C57BL/6 miceMale

Model: Thioacetamide-induced acute liver injury in rats and mice

Dioscin lowered serum ALT and AST and improved histopathological changes relative to the thioacetamide model groups in both rats and mice. It raised GSH, GSH-Px and SOD and reduced malondialdehyde, indicating reduced oxidative stress. Mechanistically it upregulated FXR and phospho-AMPKalpha with do…

Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.

Loading the evidence…